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Background: Treatment of Alzheimer’s disease with acetylcholinesterase inhibitors can result in symptomatic
benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate
relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients
treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response.
Methods: A post hoc analysis was conducted using data from a large, 24-week, randomized, double-blind,
international study enrolling patients with moderate to severe Alzheimer’s disease (baseline Mini-Mental State
Examination [MMSE], 0-20) (NCT 00478205). Cognitive changes in subgroups of patients based on selected baseline
and demographic characteristics were compared using the least squares mean changes in Severe Impairment
Battery scores at Week 24. Univariate and multivariate analyses were also performed.
Results: Donepezil 23 mg/d provided statistically significant incremental cognitive benefits over donepezil 10 mg/d
irrespective of baseline functional severity, measured by scores on the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living-severe version (P < 0.05). When patients were categorized by baseline cognitive
severity (MMSE score), significant benefits of donepezil 23 mg/d over 10 mg/d were seen in both subgroups when
based on MMSE scores of 0-9 versus 10-20 (P < 0.02 and P < 0.01, respectively), and in the more severe subgroup
when based on MMSE scores of 0-16 versus 17-20 (P < 0.0001 and P > 0.05). Statistically significant incremental
cognitive benefits of donepezil 23 mg/d over 10 mg/d were also observed regardless of age, gender, weight, or
prestudy donepezil 10 mg/d treatment duration (P < 0.05). In the multivariate analysis, the only significant
interaction was between treatment and baseline MMSE score.
Conclusions: The cognitive benefits of donepezil 23 mg/d over 10 mg/d were achieved regardless of the patient’s
age, gender, weight, duration of prior donepezil 10 mg/d, and functional severity. The influence of baseline
cognitive severity on response seemed to be dependent on the level of impairment, with cognitive benefits of
donepezil 23 mg/d over 10 mg/d most apparent in those patients at a more advanced stage of disease. These data
may be useful in helping practicing physicians make informed decisions for their patients with advanced
Alzheimer’s disease.
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Donepezil is a reversible and highly selective acetylcholin-
esterase inhibitor (AChEI) that is approved for the
symptomatic treatment of Alzheimer’s disease (AD). In
numerous clinical trials since 1997, donepezil 5 and
10 mg/d has been shown to provide clinical benefits, with
acceptable tolerability in the core symptom domains of
cognition, global functioning, and function in activities of
daily living [1]. Although both 5 and 10 mg doses have
been shown to be effective in AD, an early systematic
review of donepezil treatment and several subsequent
clinical trials have indicated a relationship between bene-
fits in cognition and higher donepezil dose [2-5]. More-
over, the cognitive benefits of a higher donepezil dose
seem to be most prominent at more advanced stages of
AD [4,5].
In 2010, a higher daily dose of donepezil (23 mg) was
approved by the US Food and Drug Administration for
the treatment of moderate to severe AD. This approval
was based on results from a large phase 3 clinical trial
comparing the 23 mg/d donepezil dose with the stand-
ard 10 mg/d donepezil dose [6]. In that trial, donepezil
23 mg/d provided statistically significant cognitive bene-
fits over those achieved with donepezil 10 mg/d, as mea-
sured by the Severe Impairment Battery (SIB). On the
co-primary measure of global function (the Clinician’s
Interview-Based Impression of Change-plus caregiver
input [CIBIC-plus]), no significant benefit was observed
with higher-dose versus standard-dose donepezil.
Although symptomatic benefits have been widely
reported with donepezil and other AChEIs, treated pa-
tients typically respond variably. For example, in a pooled
analysis of data from studies of donepezil 10 mg/d in pa-
tients with severe AD, 66.8% of donepezil-treated patients
showed stabilized or improved scores on the SIB; however,
in approximately one quarter of these “responding”
patients, SIB scores were stabilized or improved less than
4 points, whereas in around one third of patients, SIB
scores had improved by at least 12 points [7]. A number
of studies have investigated whether candidate factors,
such as patient age, the rate of pretreatment decline, the
extent of medial temporal lobe atrophy, and the level of
cognitive impairment [8-11] might influence response to
AChEI treatment among patients with AD.
Two specific post hoc analyses have previously been
performed. These examined the influence of memantine
use and geographic region (US versus non-US subgroups)
on respective efficacy outcomes with donepezil 23 mg/d
and 10 mg/d using data from the clinical trial comparing
the 2 donepezil doses [12,13]. In these analyses, donepezil
23 mg/d provided cognitive benefits over donepezil
10 mg/d, regardless of concomitant memantine use and in
both the US-based and non-US-based subgroups, indicat-
ing that memantine use and geographic location appear tohave no direct substantial influence over the cognitive
benefits of higher-dose versus standard-dose donepezil
[12,13]. The objective of the current analysis was to fur-
ther investigate relationships between other selected base-
line characteristics/ demographics (i.e., characteristics/
demographics not previously studied in post hoc analysis)
and cognitive response in patients receiving either done-
pezil 23 mg/d or donepezil 10 mg/d and to identify factors
potentially influencing response. Since the original study
compared 2 active therapies for AD, this analysis focused
on the possible influence of these baseline factors on incre-
mental benefits of higher-dose donepezil over standard-
dose donepezil. Better understanding of easily identifiable
factors influencing response to donepezil 23 mg/d versus
10 mg/d would be useful for generating hypotheses that, if
confirmed, could provide treating physicians with informa-




A comprehensive description of the original trial methods
has been published previously [6]. Briefly, this 24-week,
randomized, parallel-group, double-blind, multinational
trial enrolled patients with a diagnosis of probable AD
with a Mini-Mental State Examination (MMSE) score of 0
to 20 (moderate to severe) and a SIB score of ≤ 90. Eligible
patients had been receiving donepezil 10 mg/d for at least
3 months prior to screening. Patients were randomized in
a 2:1 ratio to transition to donepezil 23 mg/d or to
continue treatment with donepezil 10 mg/d (see
Additional file 1). Patients were eligible if taking daily
doses of ≤ 20 mg memantine for at least 3 months prior to
screening. Patients were stratified by concomitant use of
memantine, but memantine was not considered a study
medication and was not provided to patients during the
trial, nor was there monitoring of adherence. Primary effi-
cacy end points were SIB total score change from baseline
to Week 24 and the CIBIC-plus overall change score at
Week 24. Secondary efficacy end points included
Alzheimer’s Disease Cooperative Study-Activities of
Daily Living-severe version (ADCS-ADL-sev) and
MMSE score changes from baseline to Week 24. Before
conducting study procedures, investigators obtained
written informed consent from each patient, if possible,
or from the patient’s legal guardian or representative. If
a patient was unable to provide written consent, verbal
assent was required for participation, and a caregiver
was required to provide separate written informed con-
sent in the study. The protocol and informed consent
form for the original study were approved by the inde-
pendent ethics committee/institutional review board
for each research site and conformed to the principles
of the World Medical Association Declaration of
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reviewed and deemed appropriate by the FDA and
other regulatory agencies.
Relationship of response to baseline features
A post hoc analysis was conducted to evaluate the rela-
tionships between selected baseline patient characteris-
tics or demographics and cognitive response in patients
treated with either donepezil 23 mg/d or donepezil
10 mg/d. All subgroup comparisons consisted of com-
paring the differences between least squares (LS) mean
changes from baseline. Least squares mean changes in
SIB scores from baseline to Week 24 (last observation
carried forward [LOCF]) were analyzed for subgroups of
patients based on baseline patient and demographic
characteristics, including age, gender, weight, prestudy
donepezil 10 mg/d treatment duration, baseline cogni-
tive severity (MMSE score), and baseline functional
severity (ADCS-ADL-sev score).
For age, weight, prestudy donepezil 10 mg/d treatment
duration, and baseline functional severity, subgroups
were defined on values above or below the overall me-
dian value. The gender subgroups were male versus
female patients. Finally, the baseline cognitive severity
subgroups were based on either traditional severe versus
moderate subpopulations (MMSE 0-9 vs MMSE 10-20)
or on patients considered to have more or less severe
cognitive impairment (MMSE 0-16 vs MMSE 17-20) as
categorized in the original study publication [6]. This
second MMSE categorization was also used to provide
an insight into the relative cognitive effects of the 2
donepezil doses in patients with moderate to severe AD
(MMSE 0-16) compared with those with mild to moder-
ate disease (MMSE 17-20).
Univariate and multivariate analyses were also performed
using data from the intent-to-treat (ITT) population (all
patients who received at least 1 dose of study medication
and who had available baseline and postbaseline data for at
least 1 of the 2 co-primary end points). For the purposes of
these analyses, “response” was defined as a change from
baseline in SIB total score (Week 24 LOCF); this was the
absolute change in SIB and, in this case, does not refer to a
therapeutic response of one donepezil dose over the other.
Variables in the models included the baseline characteris-
tics studied in the current subgroup assessments—treat-
ment (23 mg/d vs 10 mg/d), age (continuous), gender
(male vs female), weight (continuous), prestudy donepezil
10 mg/d treatment duration (continuous), baseline MMSE
score (continuous), and baseline ADCS-ADL-sev score
(continuous)—as well as the previously assessed baseline
characteristics: concomitant memantine use (yes vs no)
and geographic region (US vs non-US) [12,13]. Due to a
significant positive correlation between baseline MMSE
score and ADCS-ADL-sev score and the resultantpotential for multicollinearity, baseline ADCS-ADL-sev
score was omitted from the multivariate model. Signifi-




In total, 1467 patients were randomized to donepezil
treatment and the ITT population was 1371. Of these,
909 patients received donepezil 23 mg/d and 462 re-
ceived donepezil 10 mg/d. Demographics and mean
baseline disease characteristics were similar for both
treatment groups. Relevant baseline data for the ITT
population are shown in Table 1.
Post hoc analysis: impact of disease characteristics
Donepezil 23 mg/d provided statistically significant incre-
mental cognitive benefits (P < 0.05 for both subgroups)
over donepezil 10 mg/d irrespective of baseline functional
severity (Figure 1A).
In patients with lower functional abilities at baseline
(below the median baseline ADCS-ADL-sev score), SIB
scores increased with donepezil 23 mg/d (LS mean
change: +1.0 point) but declined with donepezil 10 mg/d
(LS mean change: -2.0 points). However, in patients with
greater functional abilities at baseline (above the median
baseline ADCS-ADL-sev score), SIB scores increased with
both donepezil doses but the magnitude of the increase
was greater with donepezil 23 mg/d than with donepezil
10 mg/d (LS mean change: +3.4 vs +2.0 points).
When baseline cognitive severity was assessed based on
traditional MMSE scores for severe and moderate disease
(MMSE 0-9 vs 10-20), significant benefits of donepezil
23 mg/d over donepezil 10 mg/d were evident in both
subgroups (P = 0.011 and P = 0.0038, respectively;
Figure 1B). In the MMSE 0-9 subgroup, SIB scores were
relatively stabilized with donepezil 23 mg/d (LS mean
change: +0.1 points), but declined with donepezil 10 mg/d
(LS mean change: -3.8 points) whereas in the MMSE 10-
20 subgroup SIB scores increased with both donepezil
doses but the magnitude of the increase was greater with
donepezil 23 mg/d than 10 mg/d (LS mean change: +3.2
vs +1.6 points). When baseline cognitive severity was
assessed based on more or less severe cognitive impair-
ment (MMSE 0-16 vs 17-20) as categorized in the original
study publication [6], significant benefits of donepezil
23 mg/d over donepezil 10 mg/d were observed for the
more severe subgroup (P < 0.0001), but not for the less se-
vere subgroup (Figure 1C). In the MMSE 0-16 subgroup,
SIB scores increased with donepezil 23 mg/d (LS mean
change: +1.6 points), but declined with donepezil 10 mg/d
(LS mean change: -1.5 points); in the MMSE 17-20
subgroup, SIB scores increased with both donepezil doses
(LS mean change: +4.3 points in both treatment groups).
Table 1 Demographics and baseline characteristics of the
intent-to-treat population
Characteristic Donepezil 23 mg/d Donepezil 10 mg/d
Age, years
Number of patients 909 462




Number of patients 909 462
Males, n (%) 335 (36.9) 175 (37.9)
Females, n (%) 574 (63.1) 287 (62.1)
Weight, kg
Number of patients 908 462
Mean (± SD) 66.7 (14.8) 66.2 (14.4)
Median 65.5 64.5
MMSE
Number of patients 908 462
Mean (± SD) 13.1 (4.99) 13.1 (4.72)
Median 14.0 14.0
ADCS-ADL-sev
Number of patients 908 461
Mean (± SD) 34.1 (10.88) 34.5 (11.19)
Median 36.0 36.0
SIB
Number of patients 907 462
Mean (± SD) 74.2 (17.58) 75.6 (16.28)
Median 81.0 82.0
CIBIS-plus
Number of patients 904 461
Mean (± SD) 4.42 (0.85) 4.38 (0.89)
Median 4.0 4.0
Duration of prestudy
donepezil 10 mg/d, weeks
Number of patients 909 462
Mean (±SD) 113.4 (108.4) 104.9 (99.2)
Median 71.9 66.3
MMSE =Mini-Mental State Examination; ADCS-ADL-sev = Alzheimer’s Disease
Cooperative Study-Activities of Daily Living Inventory, severe version;
SIB = Severe Impairment Battery; CIBIS-plus = Clinician’s Interview-Based
Impression of Severity-plus caregiver input; SD = standard deviation.
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demographics
Statistically significant incremental cognitive benefits of
donepezil 23 mg/d over donepezil 10 mg/d were ob-
served regardless of age, gender, or weight (all P < 0.05)
(Figure 2A, B, and C). For the analysis based on age(Figure 2A), SIB scores increased with donepezil 23 mg/d
(LS mean change: +1.8 points) in the lower age subgroup
(< 75 years), but declined with donepezil 10 mg/d (LS mean
change: -1.2 points). In the older age subgroup (≥ 75 years),
SIB scores improved in both treatment arms, but the
magnitude of the increase was greater with donepezil
23 mg/d than with donepezil 10 mg/d (LS mean
change: +2.8 vs +1.3 points). For the analyses based on
gender and weight, the pattern of cognitive response
was relatively similar between the respective subgroups
(Figure 2B and C).
Post hoc analysis: impact of treatment characteristics
Statistically significant incremental cognitive benefits of
donepezil 23 mg/d over 10 mg/d were observed regard-
less of prestudy donepezil 10 mg/d treatment duration
(P < 0.05) (Figure 3).
The duration of prestudy donepezil 10 mg/d use
(< 68.3 weeks vs ≥ 68.3 weeks) did not influence the mag-
nitude of the effect when patients were subsequently
treated with donepezil 23 mg/d; SIB scores increased with
donepezil 23 mg/d (LS mean change: +3.4 points in the
shorter duration subgroup and +1.9 points in the longer
duration subgroup) but only marginally increased or stabi-
lized with the donepezil 10 mg/d (LS mean change: ≤ +0.6
points in both subgroups; Figure 3).
Post hoc analysis: univariate and multivariate analyses
In the univariate model, treatment with donepezil
23 mg/d, older age, not taking concomitant memantine,
a higher baseline MMSE score, and a higher baseline
ADCS-ADL-sev score were significantly associated with
incremental changes in SIB score at Week 24 (P < 0.01).
Significant interactions were identified between treat-
ment and age (P = 0.0199) and between treatment and
baseline MMSE score (P = 0.0013). In the multivariate
model, treatment with donepezil 23 mg/d (P < 0.0001),
higher baseline MMSE scores (P < 0.0001), and not tak-
ing concomitant memantine (P = 0.0434) were the only
significant factors associated with larger increments in
SIB score at Week 24. The significant interaction be-
tween treatment and baseline MMSE score was also
retained in the multivariate model (P = 0.0013).
Discussion
Results from this post hoc analysis suggest that the cogni-
tive benefits reported from the original study of donepezil
23 mg/d versus donepezil 10 mg/d may be achieved re-
gardless of a patient’s age, gender, weight, duration of prior
donepezil 10 mg/d treatment, and functional severity. Pa-
tients transitioning to the higher dose experience signifi-
cant cognitive benefits compared with those who continue
treatment with 10 mg/d [6]. However, the current analyses
also suggest that the cognitive benefits of donepezil
Figure 1 Effect of disease characteristics on the efficacy of donepezil 23 mg/d or 10 mg/d measured by LS mean change in SIB score
from baseline to Week 24. A. Functional level. B. Severity, MMSE 0-9 or 10-20. C. Severity, MMSE 0-16 or 17-20.
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with more advanced cognitive and/or functional deficits.
In previous studies, patient age has shown a variable
influence on response. For example, Evans et al. [8]
found a significantly greater improvement in patients
treated with donepezil who were aged ≤ 65 years (com-
pared with age > 65 years), whereas Connelly et al. [9]
found no effect of patient age on response to AChEI
treatment. In the current study, age did not appear to in-
fluence the benefits of donepezil 23 mg/d over 10 mg/d,
but younger patients showed worse overall responsescompared with older patients in the dichotomous ana-
lysis and older age was significantly associated with SIB
improvement in the univariate analysis. This observation
could reflect different disease features and/or causality
(genes, environmental factors) or an association of youn-
ger age with a more aggressive disease course (faster
progression) [14-17]. Younger patients may also be more
likely to possess the apolipoprotein E4 allele [18], which
may influence cognitive decline [19].
Gender and weight had little effect on the response to
higher-dose donepezil. Although results from this analysis
Figure 2 Effect of patient characteristics/demographics on the efficacy of donepezil 23 mg/d or 10 mg/d measured by LS mean
change in SIB score from baseline to Week 24. A. Age. B. Gender. C. Weight.
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tor for the cognitive benefits of donepezil 23 mg/d, prior
safety analyses have indicated that patients with very low
body weight may be more likely to experience treatment-
emergent adverse events upon transition to the higher
donepezil dose. Patient weight must therefore be taken
into account when considering the tolerability of done-
pezil 23 mg/d [6,20].
In terms of the studied treatment characteristics, the
duration of prestudy treatment with 10 mg/d donepezil
does not appear to influence the magnitude of effect ofdonepezil 23 mg/d versus 10 mg/d. Although not
assessed in the subgroup analysis, concomitant meman-
tine use was included as a variable in the statistical
models and not taking memantine was independently
associated with incremental changes in SIB score. While
this outcome appears to contrast with previous data on
the benefits of donepezil and memantine combination
therapy [21], there are clear differences in study design
and analysis methodology between the current and prior
trials. Furthermore, the modeling results do not rule out
baseline disease severity as an influencing factor in the
Figure 3 Effect of prior 10 mg treatment duration on the efficacy of donepezil 23 mg/d or 10 mg/d measured by LS mean change in
SIB score from baseline to Week 24.
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in patients receiving donepezil.
With respect to the assessed disease characteristics,
patient subgroups with less severe baseline disease
(higher ADCS-ADL-sev and MMSE scores) showed the
greatest level of SIB improvement with both donepezil
23 mg/d and donepezil 10 mg/d. However, the results
presented here indicate that the differential between the
effects of donepezil 23 mg/d and donepezil 10 mg/d was
greatest in patients with more severe disease (lower
ADCS-ADL-sev and MMSE scores). Indeed, the cogni-
tive benefits of donepezil 23 mg/d compared with
donepezil 10 mg/d were most apparent in those patients
who were at a more advanced stage of disease at study
baseline. The suggestion that more severe patients may
be more likely to respond to an increase in donepezil
dose appears to be further supported by the univariate
and multivariate models. As expected these models indi-
cated that higher baseline MMSE scores are associated
with incremental changes in SIB score, regardless of the
donepezil dose; however, the presence of a significant
interaction between treatment and baseline MMSE indi-
cates that the influence of baseline MMSE on the
change in SIB score during the study was significantly
different between the donepezil 23 mg/d and 10 mg/d
treatment groups.
There is a scientific rationale for why patients with more
severe AD may obtain greater benefit from a daily dose of
donepezil greater than 10 mg [22]. First, in patients re-
ceiving 10 mg/d of donepezil, the extent of acetylcholin-
esterase inhibition as measured by PET imaging is no
greater than 40% [23,24]. Second, examination of brain
tissue has demonstrated more pronounced cholinergic
deficit in patients who have more severe clinical symp-
toms [25]. As a result, patients with more severe disease
may require a greater amount of acetylcholinesterase in-
hibition in order to achieve an optimal degree of cholin-
ergic stimulation, which a higher dose of donepezil may
provide [22].While the results of these post hoc analyses are con-
sistent with the primary outcomes observed in the ori-
ginal study, they must be viewed cautiously. They were
not separately powered for significance and their inter-
pretation must be considered in view of the demograph-
ics chosen and particularly in light of clinical experience.
Moreover, data on other characteristics, for example the
rate of pre-treatment cognitive decline, were not avail-
able and therefore their influence on the SIB outcomes
could not be assessed. Furthermore, the findings are
based on post hoc subanalyses, which were not pro-
spectively defined, and thus these observations can only
generate exploratory hypotheses, which will require pro-
spective confirmation.
Conclusions
The findings of this post hoc analysis suggest that the cog-
nitive benefits of donepezil 23 mg/d over donepezil
10 mg/d may be achieved regardless of a patient’s age,
gender, weight, prior duration of donepezil 10 mg/d treat-
ment, and functional severity, and that these incremental
benefits may be more evident in patients with more ad-
vanced AD. Physicians faced with making decisions about
the optimum treatment for their patients with AD need
reliable information regarding timing and doses of treat-
ment. The data from the current analyses may be useful
for physicians and other prescribers treating patients with
advanced AD, particularly when the illness is progressing
despite treatment with donepezil 10 mg.
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